See the PATTRns | Homepage

Transthyretin amyloidosis (ATTR) is a systemic, progressive and potentially fatal disease that is frequently under-recognised due to its non-specific and heterogenous manifestations^1–3

TAKE ACTION.

Early suspicion can lead to timely diagnosis of ATTR amyloidosis and prompt treatment, which may slow disease progression^1,4–6

If you suspect ATTR amyloidosis, it is important to refer your patients to the National Amyloidosis Centre to be assessed

It is important to suspect ATTR amyloidosis signs and symptoms to facilitate earlier diagnosis and treatment¹

Recognise the signs and symptoms of ATTR amyloidosis

SEE THE SIGNS AND SYMPTOMS

In most patients with ATTR-CM, misdiagnosis or delayed diagnosis may lead to irretrievable loss of quality of life and disease progression of polyneuropathic and cardiac symptoms^1,6

Early diagnosis and referral are essential

DISCOVER DIAGNOSTIC TOOLS

ATTR=transthyretin amyloidosis; ATTR-CM=transthyretin amyloidosis with cardiomyopathy.

References: 1. Nativi-Nicolau JN, et al. Heart Fail Rev. 2022;27(3):785–793; 2. Adams D, et al. J Neurol. 2021;268(6):2109–2122; 3. Gertz MA, et al. BMC Fam Pract. 2020;21(1):198; 4. Gonzàlez-Duarte, et al. Neuro Ther. 2020;9:135–149; 5. Keohane D, et al. Amyloid. 2017;24(1):30–36; 6. Rozenbaum MH, et al. J Comp Eff Res. 2021;10(11):927–938.

GB-62815 I April 2025